acelarin

Ligand id: 7389

Name: acelarin

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 11
Hydrogen bond donors 4
Rotatable bonds 12
Topological polar surface area 171.49
Molecular weight 581.16
XLogP 4.1
No. Lipinski's rules broken 2

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Acelarin is in clinical trial in the ProGem1 phase I study, for the treatment of advanced solid tumours.
Mechanism Of Action and Pharmacodynamic Effects
To become an active antimetabolite, gemcitabine must be sequentially phosphorylated to the mono-, bi- and finally tri-phosphate forms (dFdCMP, dFdCDP and dFdCTP respectively). Adding the phosphoramidate effectively pre-phosphorylates the gemcitabine avoiding the first essential and rate-limiting phosphorylation step normally requiring deoxycytidine kinase (DCK, P277072]. In sum, the acelerin nucleoside has more effective antimetabolite activity than gemcitabine [1-2] and is already proving more efficacious in the clinical setting.